The study’s findings suggest that GFAP, NfL, tau, UCH-L1, ACTH, and AgRP exhibit potential as biomarkers for differentiating spontaneous ICH patients from healthy controls, but these findings should be interpreted with caution and cannot be expected to translate directly into clinical practice.
Abstract
Background and Purpose The timing of diagnosis is a critical factor that significantly impacts medical treatment and patient outcomes in individuals with intracerebral hemorrhage (ICH). The study primarily aimed to evaluate the diagnostic potential of four brain-specific biomarkers, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), tau, and ubiquitin C-terminal hydrolase-L1 (UCH-L1) to differentiate CT-confirmed ICH patients from healthy controls. Secondary aims included comparing results between younger (18-59 years) and older (≥60 years) ICH patients and exploring neuroendocrine hormone levels (adrenocorticotropic hormone [ACTH], agouti-related peptide [AgRP], ciliary neurotrophic factor [CNTF], and growth hormone [GH]) as potential diagnostic tools. Methods Serum samples were collected from consecutive adult patients with CT-confirmed ICH diagnoses on days 1 (first 24 hours), 2, 3, 7, and 14 for biomarker analyses in a pilot study. A total of 71 patients and 30 healthy controls were included in the analysis. Results Serum concentrations of four brain-specific biomarkers demonstrated significant differentiation between ICH patients and controls at all assessed time points (Days 1, 2, 3, 7, and 14; all p<0.05), with similar significant elevations observed for NfL, tau, and UCH-L1. Day 1 GFAP levels were markedly higher in ICH patients (median 9598 pg/mL compared with healthy controls (39.2 pg/mL; p<0.05). No significant differences were found between young and aged adult ICH subgroups. Neuroendocrine ACTH and AgRP levels were significantly higher in ICH patients compared to controls on both measured time points (Days 1 and 7). Conclusions The study’s findings suggest that GFAP, NfL, tau, UCH-L1, ACTH, and AgRP exhibit potential as biomarkers for differentiating spontaneous ICH patients from healthy controls. However, given the limitations of the current study design, these findings should be interpreted with caution and cannot be expected to translate directly into clinical practice. Further research is needed to assess these biomarkers’ roles in distinguishing stroke types and predicting ICH outcomes.
Chronic traumatic encephalopathy (CTE) is a progressive tauopathy associated with repetitive head impacts (RHIs) and is currently confirmed only at autopsy. The absence of a validated antemortem diagnostic limits individual risk assessment, clinical trial enrollment, and differentiation from disorders such as Alzheimer...
Mild traumatic brain injury is a common reason for presentation to emergency departments, where management relies heavily on cerebral computed tomography (CT-scan), a radiological examination that is both radiation-emitting and overused. The measurement of blood biomarkers of cerebral origin provides a complementary to...
Vincent Sapin· Annales Pharmaceutiques Fran...· 0 citations
OBJECTIVE
The authors sought to identify plasma glial fibrillary acidic protein (GFAP) and ubiquitin c-terminal hydrolase-L1 (UCH-L1) cutoffs corresponding to a range of high positive predictive values (PPVs) for detecting intracranial pathology on CT and detecting pathology on MRI (when CT is negative) in patients who...
Shawn R. Eagle, John K. Yue, A. Puccio et al.· Journal of Neurosurgery· 1 citation
Plasma NfL may support the differentiation between clinically diagnosed MSA and PD, including early in the disease course, and the limited added value of multimarker panels supports a simpler and more immediately translatable NfL-first strategy for diagnostically uncertain parkinsonism.
BACKGROUND
Multiple sclerosis (MS) diagnosis depends on clinical and magnetic resonance imaging (MRI) data; the need for confirmatory cerebrospinal fluid (CSF) biomarkers for differential diagnosis is a crucial step.
OBJECTIVE
We aim to investigate and compare the diagnostic value of CSF markers (e.g., chitinase 3-li...
Basant Rashad, Sohair K. Sayed, Tarek A. Rageh et al.· Clinica chimica acta; intern...· 0 citations
BACKGROUND
Neurofilament light chain (NfL) is an established biomarker for amyotrophic lateral sclerosis (ALS). However, it remains unclear whether biomarkers reflecting amyloid-β metabolism (Aβ), tau (phosphorylated tau, pTau), and astrogliosis (glial fibrillary acidic protein, GFAP) can complement NfL in clinical app...
Kazuki Obara, S. Janelidze, Daisuke Ito et al.· EBioMedicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.